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 Subendothelial retention of LDL by the proteoglycans 
of the extracellular matrix is the key initiating event in the 
development of atherosclerosis ( 1, 2 ). Modifi cation of the 
retained LDL by lipolytic and proteolytic enzymes present 
in the arterial intima induces aggregation and/or fusion 
of the modifi ed LDL particles ( 3 ). Aggregation of LDL 
particles increases their binding strength to the proteogly-
cans, thus enhancing the extracellular retention of LDL 
in the arterial intima ( 3, 4 ). SMase, an enzyme locally 
secreted by endothelial cells and macrophages in the ar-
teries ( 5, 6 ), has been shown to be one of the enzymes re-
sponsible for LDL aggregation during atherogenesis ( 3 ). 
Actually, LDL particles isolated from atherosclerotic arter-
ies resemble LDL aggregates generated by incubation of 
LDL with SMase in vitro ( 7 ). Importantly, genetic defi -
ciency of secretory SMase associates with a reduction of 
intimal lipoprotein retention and atherosclerotic lesions 
in mice, thereby providing evidence for a causal role for 
secretory SMase in the development of atherosclerotic le-
sions in vivo ( 8 ). 
 Therapeutic strategies to treat atherosclerosis have 
been developed using apoA-I mimetic peptides ( 9 ). These 
18 amino acid peptides have no sequence homology to 
apoA-I, but they possess the same class A amphipathic 
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protein concentrations, which were determined by BCA protein 
assay kit (Pierce, Rockford, IL) using BSA as the standard. 
 Incubation of 4F with LDL 
 To evaluate the effects of the peptides on SMase-induced LDL 
aggregation, the experiments were performed under several con-
ditions as described subsequently. 
 Modifi cation of LDL in the presence of 4F.  Human LDL particles 
(1 mg/ml) were incubated with 200 mU/ml (20.8 nM) of  Bacillus 
cereus SMase (bcSMase) (Sigma-Aldrich) in 20 mM Tris (pH 7.0) 
buffer containing 150 mM NaCl, 2 mM CaCl 2 , and MgCl 2 at 37°C 
in the presence or absence of different concentrations of apoA-I 
mimetic peptide (molar ratio of peptide to apoB-100 ranging 
from 1:1 to 20:1) for the indicated times. LDL particles (1 mg/ml) 
were also modifi ed with 50 µg/ml of human recombinant SMase 
(a kind gift from Genzyme) in 20 mM MES buffer (pH 5.5–6.5) 
containing 150 mM NaCl and 50 µM ZnCl 2 at 37°C in the pres-
ence or absence of different concentrations of apoA-I mimetic 
peptide for the indicated times, after which the lipolysis was 
stopped by addition of EDTA (fi nal concentration: 10 mM) and 
samples were placed on ice. The degree of SMase-induced lipoly-
sis was determined by measuring the amounts of phosphorylcho-
line in the samples using Amplex Red phosphorylcholine kit 
(Molecular Probes). 
 Removal of unbound 4F before LDL modifi cation.  LDL particles 
(2 mg/ml) were incubated with L-4F at 10:1 molar ratio of L-4F 
to apoB-100 in LDL buffer at 37°C for 30 min, followed by exten-
sive dialysis against LDL buffer at 4°C using dialysis membrane 
with molecular weight cutoff of 12,000–14,000 Da. After removal 
of the unbound peptides, the L-4F-treated LDL (referred to 
as 4F-pretreated LDL hereinafter) and control LDL particles 
(1 mg/ml) that had not been incubated with the 4F peptide were 
modifi ed with bcSMase as described previously. 
 Incubation of 4F with SMase-premodifi ed LDL.  LDL particles 
(1.25 mg/ml) were incubated with 200 mU/ml of bcSMase 
(Sigma-Aldrich) in 20 mM Tris (pH 7.0) containing 150 mM 
NaCl, 2 mM CaCl 2 , and MgCl 2 at 37°C. After an incubation for 
15 min, lipolysis was stopped by the addition of EDTA (fi nal 
concentration: 10 mM). Native or bcSMase-treated LDL particles 
(1 mg/ml) were incubated in 20 mM Tris (pH 7.0) containing 
150 mM NaCl at 37°C in the presence or absence of L-4F at 10:1 
molar ratio of L-4F to apoB-100 for the indicated times. 
 Analysis of LDL aggregation and enzyme kinetics 
of 4F-bound LDL particles 
 Aggregation of the LDL samples modifi ed as described previ-
ously was followed by measuring the absorbance of the LDL 
samples at 405 nm. The sizes of the aggregated particles were 
determined by dynamic light scattering (DLS) (ZetasizerNano; 
Malvern) as described previously ( 26 ). 
 The control LDL and 4F-pretreated LDL particles at 10:1 molar 
ratio of L-4F to apoB-100 (0.1–1.5 mg/ml) were incubated with 
bcSMase in 20 mM Tris (pH 7.0) containing 150 mM NaCl, 2 mM 
CaCl 2 , and MgCl 2 at 37°C for 30 min, and the degree of SMase-
induced lipolysis was determined by Amplex Red phosphorylcho-
line kit.  K m ,  V max , and  K cat were determined from the Lineweaver-Burk 
plot.  K cat is the turnover number; the number of substrate mole-
cules each enzyme site converts to product per unit time. 
 Analysis of modifi ed LDL by size-exclusion 
chromatography 
 The fast-protein liquid chromatography profi les of control 
LDL and LDL modifi ed under different conditions were ana-
lyzed using a high-resolution size-exclusion chromatography 
(SEC) Superose HR6 column connected to the ÄKTA chroma-
tography system (GE Healthcare). The samples were centrifuged 
helical structure as apoA-I ( 10–13 ). Among this family of 
apoA-I mimetics, the most extensively studied peptide 4F 
is composed of 18 amino acids with the sequence of Ac-D-
W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH 2 ( 10, 12 ). The 4F pep-
tide functionally mimics many of the biological properties 
of apoA-I, and it is both anti-infl ammatory and antiathero-
genic ( 10–13 ). In various mouse models of atherosclerosis, 
4F signifi cantly reduced the development of atheroscle-
rotic lesions, being most effective during early atherogenesis 
( 14, 15 ). 
 Several potential mechanisms by which 4F might exert 
its antiatherogenic properties have been proposed. The 
4F peptide induces HDL remodeling, which includes for-
mation of pre-  -HDL with elevated paraoxonase activity, 
and results in promotion of cholesterol effl ux and conver-
sion of proinflammatory HDL into anti-inflammatory 
HDL ( 14 ). The antiatherogenic properties of 4F most 
likely involve binding and sequestering oxidized lipids, 
which play a critical role in atherosclerosis ( 16 ). Indeed, 
4F avidly binds to oxidized phospholipids and oxidized 
unsaturated fatty acids with affi nity four to six orders of 
magnitude higher than apoA-I ( 17 ). Given the high affi n-
ity of 4F for oxidized phospholipids, which might be pres-
ent in undetectable amounts in freshly isolated lipoproteins 
( 18, 19 ), it is plausible to assume that an apoA-I mimetic 
peptide would also bind to LDL particles. Indeed, 4F was 
shown to bind to LDL particles, especially when LDL was 
supplemented with oxidized lipids ( 20 ). Moreover, previ-
ous studies have demonstrated that amphipathic   -helix-
containing apos block phospholipase C (PLC)-induced 
LDL aggregation ( 21, 22 ). Based on the previous informa-
tion, we hypothesized that 4F would affect the susceptibil-
ity of LDL to SMase-induced aggregation. We found that 
4F interacts with LDL particles and stabilizes them by pre-
venting SMase-induced conformational changes in apoB-100 
and can ultimately block SMase-induced LDL aggregation 
and the resulting increase in LDL retention. 
 MATERIALS AND METHODS 
 Peptides 
 The amino acid sequence of L-4F is Ac-DWFKAFYDKVAEK-
FKEAF-NH 2 . The inactive control peptide called scrambled L-4F 
has the same overall amino acid composition as L-4F but in a se-
quence that does not promote amphipathic   -helix formation 
(Ac-DWFAKDYFKKAFVEEFAK-NH 2 ). 4F peptides were synthe-
sized by the solid phase peptide synthesis method previously de-
scribed ( 23 ). 
 Isolation of LDL 
 Human plasma was obtained from healthy volunteers (Finnish 
Red Cross Blood Service). LDL from human or mouse plasma (d = 
1.019–1.050 g/ml) was isolated by sequential ultracentrifugation 
( 24 ) or by rapid sequential fl otation ultracentrifugation using KBr 
for density adjustment ( 25 ). Lipoprotein stock solutions were di-
alyzed against LDL buffer (150 mM NaCl, 1 mM EDTA, pH 7.4), 
fi ltered, stored at 4°C, and used within 2 weeks, during which no 
changes in protein conformation and particle size were observed. 
The amounts of lipoproteins are expressed in terms of their total 
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for 1 h at 37°C. Unbound LDL particles were removed, and the 
wells were washed with 20 mM Tris (pH 7.0) buffer containing 
30 mM NaCl, 2 mM MgCl 2 , and 2 mM CaCl 2 , and the bound lipo-
proteins were detected by a commercial cholesterol kit (Amplex 
Red; Molecular Probes). Specifi c binding to proteoglycans was 
calculated by subtracting the amounts of the lipoproteins bound 
to the BSA-coated wells from the amounts of lipoproteins bound 
to the proteoglycan-coated wells. 
 Animal study 
 Animal experiments and the protocols were approved by the 
National Animal Experiment Board. The effect of the peptide 
on LDL aggregation in vivo was studied in 5-month-old male 
LDLR   /   ApoB 100/100 mice fed with a high-fat, Western-type diet 
(TD 88173; Harlan Teklad) for 6 weeks. The peptides were dis-
solved in DMSO, further diluted into NaCl, and 100 µg/mouse of 
either L-4F (n = 7) or only DMSO (control, n = 6) was injected via 
tail vein in 150 µl volume. For the injection, the mice were gently 
sedated with xylazine (0.1 mg/10 g) and ketamin (0.8 mg/10 g). 
One hour after the injection, the animals were euthanized, and 
EDTA-Plasma was collected for LDL isolation. LDL particles 
(0.15 mg/ml) were incubated with 200 mU/ml bcSMase (Sigma-
Aldrich) in 20 mM Tris (pH 7.0) buffer containing 150 mM 
NaCl, 2 mM CaCl 2 , and MgCl 2 at 37°C for indicated times. The 
sizes of the LDL particles were determined by DLS (Zetasizer-
Nano; Malvern). 
 Atomistic molecular dynamics simulations 
 Models .  To study the interactions of 4F with LDL lipids, pla-
nar trilayer systems were computationally used as a model for 
protein-free LDL. The lipids used in the model (see below) were 
POPC, palmitoyl SM, cholesterol, cholesteryl oleate, and ce-
ramide, whose structures are well known. The model for the 
structure of the 4F peptide was obtained as a homology model 
(L3F, L14F) from the 2F peptide ( 30 ) (PDB entry 2F95) by using 
the Bodil software ( 31 ). The trilayer-4F system was surrounded by 
water with salt (NaCl; see below). 
 The force fi elds for POPC, SM, and cholesterol were taken 
from the Slipids parameter set ( 32–34 ), whereas cholesteryl ole-
ate and ceramide were parameterized to be compatible with it 
(see supplementary Materials and Methods). The Amber03 force 
fi eld was used for the peptides, and the TIP3P model was used for 
water ( 35 ). All simulations reported in this paper were per-
formed with the GROMACS 4.6.× simulation package ( 36 ). 
 Molecular dynamics simulation setup.  The peptide structure was 
equilibrated by simulating it in water and simultaneously gradu-
ally removing restraints from its structure ( Peptide_water simula-
tions in  Table 1 ).  The heavy atoms were fi rst restrained for 100 ps 
followed by a 20 ns simulation with the backbone atoms restrained. 
Finally, the unrestrained peptide structure was allowed to relax 
in water for either 20 ns or 1 µs (see below). 
at 10,000  g for 10 min at 4°C, and a 50 µl aliquot of the superna-
tant was injected into the column and eluted with PBS buffer at a 
fl ow rate of 0.5 ml/min. The degree of aggregation is expressed 
as a percentage of the 280 nm absorbance of peak I of modifi ed 
LDL to the 280 nm absorbance of peak I of control LDL. Peak 
areas were calculated by integration of the 280 nm absorbance 
using the Unicorn 5.2 software. 
 Circular dichroism spectroscopy 
 The control and 4F-pretreated LDL particles (1 mg/ml) were 
modifi ed with bcSMase in 20 mM Tris (pH 7.0) buffer containing 
150 mM NaCl, 2 mM MgCl 2 , and 2 mM CaCl 2 . Samples of control 
LDL and 4F-pretreated LDL (50   g/ml) were analyzed by circu-
lar dichroism (CD) at different time points as described previ-
ously ( 26, 27 ). 
 Tryptophan fl uorescence spectroscopy 
 Fluorescence emission spectra were measured for control LDL 
or 4F-pretreated LDL particles (0.1 mg/ml) in 20 mM Tris (pH 
7.0) buffer containing 150 mM NaCl, 2 mM MgCl 2 , and 2 mM 
CaCl 2 using a PerkinElmer LS 55 Fluorescence Spectrometer. 
The fl uorescence cell holder was thermostatically maintained at 
37 ± 0.1°C. The spectra were recorded from 305 to 450 nm with 
excitation at 295 nm and 5 nm bandwidth for excitation and 
emission. For each sample, 10 spectra were averaged, and blank 
measurements were subtracted. 
 Preparation and characterization of human aortic 
proteoglycans 
 Proteoglycans from the intima media of human aortas ob-
tained at autopsy within 24 h of accidental death were prepared 
essentially by the method of Hurt-Camejo et al. ( 28 ) and charac-
terized as previously ( 29 ). 
 Binding of human LDL to proteoglycans 
 To examine the effect of 4F on the ability of SMase-modifi ed 
LDL to bind to human aortic proteoglycans, control LDL and 
4F-pretreated LDL particles (molar ratio of peptide to apoB-100 
ranging from 2.5:1 to 20:1) were modifi ed with bcSMase for 
15 min in 20 mM Tris (pH 7.0) buffer containing 150 mM NaCl, 
2 mM MgCl 2 , and 2 mM CaCl 2 . Aliquots of the control and 4F-
pretreated LDL particles were used for proteoglycan binding 
study. 
 The wells in polystyrene 96-well plates were coated with 100   l 
of human aortic proteoglycans (50   g/ml) or fatty acid-free BSA 
(5 mg/ml) at 4°C overnight and blocked with 5% fatty acid-free 
BSA, 1% fat-free milk powder, and 0.05% Tween 20 in PBS for 
1 h at 37°C as described previously ( 4 ). The LDL aliquots were 
added to the proteoglycan- or BSA-coated wells in 20 mM Tris 
(pH 7.0) buffer containing 150 mM NaCl, 2 mM MgCl 2 , and 
2 mM CaCl 2 and 1% fatty acid-free BSA, and the plate was incubated 
 TABLE 1. The names, descriptions, and durations of the atomistic simulations in this study 
Simulation Set Confi guration and Simulations Duration
 Trilayer_equil Both trilayer models (with ceramide and with SM) equilibrated in experimental 
surface tension without the peptide present.
Both trilayers: 650 ns
 Peptide_water The 4F peptide simulated in water, while the restraints were gradually discarded. 100 ps + 20 ns + 1 µs/20 ns
 Helix_trilayer Two helical peptides interacting with the trilayers. Six simulations (one extended) 
with varying initial confi gurations for both SM and ceramide.
Both trilayers: 5 × 
(150/200 ns) + 600 ns
 Unfolded_trilayer One peptide interacting with the trilayers. The partially unfolded peptide 
structure was taken from the end of the  Peptide_water simulation.
Both trilayers: 400 ns
 Free_energy A total of 21 umbrella windows for both trilayers. One peptide with the trilayer. 
Initial frames were extracted from the  Unfolded_trilayer simulation.
Most windows 50 ns, some 
extended to 200 ns
 Annealing The end structures of the extended  Helix_trilayer simulations for the trilayer 
with SM heated up and subsequently cooled down.
3 target temperatures, 
100 ns each
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 The simulation parameters were compatible with the Slipids 
force fi eld in all of the conducted simulations (see the supple-
mentary Materials and Methods for details). A summary of the 
performed simulations, which covered approximately 10 µs, is 
given in  Table 1 . 
 Analysis of atomistic simulation data.  The electrostatic poten-
tial profi le along the trilayer normal was obtained by integrating 
the partial charge distribution of the system twice. This was per-
formed with a GROMACS tool g_potential. 
 The deuterium order parameter   S CD characterizing lipid hy-
drocarbon chains’ conformational order is defi ned as 
 ?? ?? ?2CD (3 cos2 )1S  
 Here, ? is the angle between a carbon in the lipid tail and a hy-
drogen atom (deuterium in an experimental setup, hence the 
name) bound to it. The angular brackets stand for time and en-
semble averages. A value of 0.5 for   S CD refers to perfectly 
straightened hydrocarbon tails, whereas a value of 0 corresponds 
in practice to random orientation of the tails. Here, the   S CD 
profi le along the lipid tails was computed from the positions of 
the tail carbon atoms with the GROMACS tool g_order. 
 Spatially resolved deuterium order parameters were calcu-
lated with the g_lomepro tool ( 38 ). This tool assigns all lipids to 
grid points in the monolayer plane based on their location. The 
average ordering at each grid point is presented as a column of 
spheres, each of which represents a carbon in the hydrocarbon 
chain of the studied lipid type. The color of these spheres shows 
the average order parameter of the corresponding carbon at that 
grid point, whereas their vertical location shows the average 
depth at which the corresponding carbon resides in that grid 
point. The data in each grid point are time-averaged as well as 
averaged over the multiple lipids visiting this grid point during 
the simulation. 
 The helical contents of the peptide were calculated, and the 
simulation snapshots were rendered with the VMD software. 
 The free energy profi les were calculated from the umbrella 
sampling simulations with the GROMACS tool g_wham, and the 
error estimates were evaluated with the bootstrapping analysis 
( 39 ). 
 Whenever comparison is made with the peptide-free system, 
the data covering the last 50 ns of the relaxation simulation (see 
Materials and Methods) are used for analysis. 
 Statistical analysis 
 Results are reported as mean ± SD. Statistical signifi cance ( P < 
0.05) was determined by two-tailed Student’s  t -test. 
 RESULTS 
 The 4F peptide blocks SMase-induced LDL aggregation 
 To study the effects of apoA-I mimetic peptides on bcS-
Mase-induced LDL aggregation, LDL particles were fi rst 
incubated with bcSMase in the absence or presence of 4F. 
The aggregation and sizes of the lipoprotein particles were 
measured at various time points. As shown in  Fig. 1A , L-4F 
blocked bcSMase-induced LDL aggregation in a dose-
dependent manner as refl ected by its ability to prevent an 
increase in turbidity of bcSMase-treated LDL.  At 10:1 or 
20:1 molar ratio of 4F to apoB-100, full protection against 
 The trilayer systems were constructed by placing a preequili-
brated cholesteryl oleate slab of 200 molecules between two lipid 
monolayers. Each of the monolayers consisted of 100 lipids and 
their composition followed that of the LDL surface monolayer 
( 37 ) with 46 mol% POPC, 17 mol% SM, and 37 mol% choles-
terol. In the model for SMase-treated LDL, all SM was replaced 
by ceramide. The systems were hydrated with 50 water molecules 
per surface monolayer lipid. NaCl (150 mM) was added to the 
water phase. The system was allowed to relax to the experimental 
surface pressure ( Trilayer_equil simulations in  Table 1 ; see also 
supplementary Materials and Methods for details) before the 
production simulations with the peptide. 
 After these relaxation simulations, the peptides were included 
in the system. We considered two situations: a lipid trilayer cor-
responding to an unmodifi ed LDL composition (with SM) and a 
system corresponding to the SMase-treated LDL composition 
(ceramide replacing SM). Multiple simulations with varying ini-
tial conditions were performed to study the interaction of the 
4F peptide with these two trilayers: either the interaction of a 
single partially unfolded peptide with the trilayer was considered, 
or two almost helical peptides were included into the system 
simultaneously. In addition, umbrella sampling simulations were 
performed. 
 In the single peptide case, called  Unfolded_trilayer in  Table 1 , 
the structure of 4F after 1 µs of the  Peptide_water simulation was 
included in the trilayer systems. For more information on the 
construction of these initial structures, see supplementary Mate-
rials and Methods. The constructed systems were simulated for 
400 ns. Snapshots of these trajectories were further used in the 
umbrella sampling simulations (see below). 
 Additional data were collected by placing two almost perfectly 
helical 4F peptides (structure after 20 ns of  Peptide_water simula-
tion) in the trilayer systems. For more details on the construction 
of these systems, see supplementary Materials and Methods. These 
systems are referred to as  Helix_trilayer in  Table 1 . Six initial con-
fi gurations with systematically varying position and orientation 
of the peptide were considered for both trilayer compositions. 
These simulations were run until the peptides properly bound to 
the trilayers. In most replicas, 150 ns was adequate, yet in some 
cases the simulations needed to be extended to 200 ns. Addition-
ally, one system with each composition was extended to 600 ns in 
order to observe long-time lipid rearrangement on the trilayer 
surface. The last 400 ns of these extended simulations was consid-
ered in the analysis. 
 The free energy profi les of the peptide interacting with the 
trilayers were obtained from umbrella sampling simulations, listed 
as  Free_energy in  Table 1 . The initial structures were extracted 
from the  Unfolded_trilayer simulations. The distance between the 
centers of mass of the peptide and the trilayer in the umbrella 
windows varied between 1 and 5 nm with a spacing of 0.2 nm. 
This distance was measured in the direction normal to the trilayer 
surface. A force constant of 500 kJ/mol/nm 2 was used for the 
harmonic restraining potential. The umbrella windows were sim-
ulated for 50 ns except for the distances between 3 and 4 nm for 
which the simulations were extended to 200 ns in order to elimi-
nate some interfacial effects. The data collected during the last 
25 ns of all simulation windows were used in the analysis. 
 Additionally, the thermal stability of the 4F conformation on 
the SM-containing trilayer surface was studied. The fi nal struc-
tures of the extended  Helix_trilayer simulations were used as start-
ing structures for the annealing simulations in which the system 
was heated up and subsequently cooled down. The temperature 
of the system was linearly increased to either 330, 350, or 370 K 
during 50 ns after which it was linearly decreased back to 310 K 
during another 50 ns. These simulations are referred to as  Anneal-
ing in  Table 1 . 
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 Fig.  1. The effect of 4F on SMase-induced LDL aggregation dur-
ing coincubation. LDL particles (1 mg/ml) were modifi ed with 
bcSMase in the absence or presence of the indicated molar ratios 
of peptide to apoB-100 at pH 7.0. The aggregation of the LDL par-
ticles was monitored by measuring the turbidity (A) and by SEC 
(B). The inset in B shows quantitative analysis of protection of L-4F 
against SMase-induced LDL aggregation at 3 and 6 h time points 
based on the SEC data. The sizes of the LDL particles were mea-
sured using DLS (C) at the indicated time points. The SMase-
induced formation of phosphorylcholine was determined by an 
Amplex Red assay (D). The results represent means ± SD of tripli-
cate wells and are representative of four independent experiments 
performed with different LDL preparations. 
 
SMase-induced LDL aggregation was observed up to 3 h of 
incubation. With prolonged incubation, the protective 
role of L-4F gradually diminished, and SMase-induced 
LDL aggregation increased. In contrast, scrambled 4F did 
not have any effect on bcSMase-induced LDL aggregation 
( Fig. 1A ). After incubation for 6 h, the ability of 4F to pro-
tect against bcSMase-induced aggregation was analyzed by 
SEC using a Superose 6 HR 10/30 gel fi ltration column 
( Fig. 1B ). Control LDL, which had been incubated with-
out bcSMase, eluted from the column as a single peak, 
corresponding to the elution volume of native LDL (peak I). 
By contrast, the elution profi le of SMase-treated LDL showed 
two peaks. Peak II, which contained aggregated LDL, 
eluted at the void volume of the column, and peak I eluted 
at a position corresponding to the elution volume of con-
trol LDL. Inclusion of L-4F in the incubation mixture ef-
fectively prevented SMase-induced LDL aggregation, as 
evidenced by a decrease in the amount of LDL eluting in 
peak II and by an increase in the amount of nonaggre-
gated LDL (peak I). Quantitative analysis of the chro-
matograms indicated that L-4F exhibited a 72% and 47% 
protection against SMase-induced LDL aggregation at 
10:1 molar ratio of L-4F to apoB-100 after 3 h and 6 h incu-
bation, respectively ( Fig. 1B , inset). We further deter-
mined the particle sizes of LDL treated with bcSMase in 
the presence of L-4F using DLS. Consistent with the ag-
gregation data, 4F dose-dependently prevented the forma-
tion of larger aggregates ( Fig. 1C ). Next, we investigated 
whether inclusion of L-4F in the incubation would affect 
the susceptibility of LDL particles to bcSMase hydrolysis 
and found that L-4F decreased the capacity of bcSMase to 
hydrolyze LDL particles in a dose-dependent manner ( Fig. 
1D ). However, when using pure SM as a substrate, 4F did 
not inhibit but rather stimulated bcSMase activity, thereby 
excluding a direct inhibitory effect of 4F on SMase (sup-
plementary Fig. 1). Taken together, the data suggest that 
4F interacted with LDL particles and rendered them less 
susceptible to SMase hydrolysis and thus blocked the 
SMase-induced LDL aggregation. 
 The 4F peptide blocks SMase-induced LDL aggregation 
at acidic pH 
 We have previously shown that acidic pH enhances 
SMase-induced LDL aggregation ( 26 ). Here, we examined 
whether L-4F would block SMase-induced LDL aggregation 
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also at acidic pH. For this purpose, LDL was treated with 
human recombinant SMase (hSMase) at pH values 5.5–6.5 
in the presence and absence of different concentrations 
of L-4F. As expected, inclusion of L-4F in the incubation 
mixture prevented increase in the turbidity of the mixture 
(i.e., it blocked hSMase-induced LDL aggregation) ( Fig. 2A ). 
 SEC data further confi rmed that L-4F possesses the ability 
to prevent hSMase-induced LDL aggregation ( Fig. 2B ). 
Particle size measurement revealed that 4F prevented the 
formation of large aggregates at acidic pH ( Fig. 2C ). Simi-
lar to the data observed at neutral pH, we found that 4F 
also diminished the capacity of hSMase to hydrolyze LDL 
particles at acidic pH ( Fig. 2D ). 
 The 4F-pretreated LDL particles are resistant 
to SMase-induced LDL aggregation 
 Next, we examined whether removal of unbound 4F be-
fore incubation of LDL with bcSMase would maintain its 
effect on SMase-induced LDL aggregation. To this end, we 
fi rst incubated LDL particles with L-4F at 10:1 molar ratio 
of 4F to apoB-100 for 30 min, followed by extensive dialysis 
to remove unbound L-4F, after which the LDL samples 
were subjected to modifi cation by bcSMase. Pretreatment 
of LDL with L-4F protected LDL from bcSMase-induced 
aggregation in a time-dependent fashion, as demonstrated 
by turbidity ( Fig. 3A ), SEC ( Fig. 3B ), and DLS methods 
( Fig. 3C ).  Again, pretreatment of LDL with L-4F decreased 
the susceptibility of LDL particles to hydrolysis by bcSMase 
( Fig. 3D ). Further detailed analysis of enzyme kinetics in-
dicated that 4F-bound LDL exhibited lower  K m ,  V max , and 
 K cat ( Table 2 ), indicating that binding of 4F to LDL parti-
cles effectively hindered the SMase from accessing the SM 
molecules in LDL particles.  
 We next studied whether 4F-induced protection from 
SMase-induced aggregation was solely due to inhibition of 
SM hydrolysis. For this purpose, LDL particles were fi rst 
 Fig.  2. The effect of 4F on SMase-induced LDL ag-
gregation at acidic pH. LDL particles (1 mg/ml) were 
modifi ed with hSMase in the absence or presence of 
the indicated molar ratios of L-4F to apoB-100 at dif-
ferent pH. The aggregation of the LDL particles was 
monitored by turbidity (A) and by SEC (B). The sizes 
of the LDL particles were measured using DLS (C) at 
the indicated time points. The formation of phos-
phorylcholine was determined by an Amplex Red 
assay (D). The results represent means ± SD of tripli-
cate wells and are representative of two indepen-
dent experiments performed with different LDL 
preparations. 
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 Fig.  3. The 4F-pretreated LDL particles are resistant to SMase-
induced LDL aggregation. LDL particles (2 mg/ml) were preincu-
bated with and without L-4F at 10:1 molar ratio of 4F to apoB-100, 
followed by extensive dialysis. Control and 4F-pretreated LDL 
(1 mg/ml) were modifi ed with bcSMase at pH 7.0, and the aggre-
gation of the LDL particles was monitored by turbidity (A) and by 
SEC (B). The inset in B shows quantitative analysis of aggregation 
based on the SEC data. The sizes of the LDL particles were mea-
sured using DLS (C) at the indicated time points. The formation of 
phosphorylcholine was determined by an Amplex Red assay (D). 
The results are representative of three independent experiments 
performed with different LDL preparations. 
 
treated with bcSMase for 15 min, followed by the addition 
of EDTA to fully inhibit the enzyme activity, and fi nally ad-
dition of 4F to the incubation mixture. Under these condi-
tions, SMase treatment induced aggregation of   40% of 
LDL particles. Addition of L-4F to SMase-premodifi ed 
LDL prevented LDL from further aggregation, as evi-
denced by turbidity and by SEC data ( Fig. 4A , B ).  Particle 
size measurement showed that the addition of L-4F pre-
vented LDL particles from forming larger aggregates 
( Fig. 4C ) but failed to diminish the size of the existing 
aggregates. Because a previous study has revealed that 
4F binds to phospholipid vesicles, where it exerts its lipid-
solubilizing ability ( 23 ), we investigated whether the pro-
tective action of 4F against SMase-induced LDL aggregation 
could be related to its lipid-solubilizing ability. We found 
that 4F slightly decreased the turbidity of SMase-treated LDL 
(supplementary Fig. 2A), possibly due to a minor lipid-
solubilizing effect ( 23 ). However, when added to SMase-
treated LDL, which exhibited almost a maximum degree 
of aggregation, 4F was unable to diminish the aggregate 
sizes (supplementary Fig. 2B), indicating that the protec-
tive action of 4F was independent of its lipid-solubilizing 
activity. 
 The 4F peptide rapidly binds to trilayer models of 
SMase-treated and untreated LDL 
 As 4F has been shown to vividly bind to lipid bilayers 
( 23 ) and also to bind to LDL particles ( 20 ), we used atom-
istic molecular dynamics simulations to investigate the in-
teractions of 4F with LDL lipids in detail using a planar 
trilayer system mimicking the lipid composition in LDL 
( Fig. 5A ).  The key objectives of the simulations were to 
unlock the forces driving 4F to the LDL surface, estimate 
the effect of SMase-conducted modifi cations to the pep-
tide-trilayer binding strength, and unravel how 4F changes 
the surface properties of LDL prior to and after SMase ac-
tion. Consideration of the action of SMase on LDL would 
require quantum-mechanical simulations due to the enzy-
matic reaction involved, and as these are not feasible, we 
effectively modeled the role of SMase by considering the 
situation prior to (system with SM) and after its effect (all 
SM replaced with ceramide). 
 First, the 4F peptide was simulated in water ( Peptide_water 
simulation) in order to fi nd the correct secondary struc-
ture of the peptide in the water phase. The average helical 
content of the 4F peptide versus time, shown in supple-
mentary Fig. 3A, was calculated to be 50.5% during the last 
500 ns of this simulation. This is signifi cantly higher than 
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 TABLE 2. The bcSMase kinetic parameters for LDL and 4F-pretreated LDL particles 
Substrate  K m (µM)  V max  (nmol/min)  K cat  (1/min)
LDL 4.25 ± 0.53 0.11 ± 0.014 54.60 ± 7.12
4F-LDL (10:1) 3.18 ± 0.07 a 0.08 ± 0.001 a 38.08 ± 0.88 a 
The control LDL and 4F-pretreated LDL particles at 10:1 molar ratio of L-4F to apoB-100 (0.1–1.5 mg/ml) 
were incubated with bcSMase. The SMase activity was determined by measuring the amounts of phosphorylcholine. 
 K m ,  V max , and  K cat were determined by Lineweaver-Burk plot. 
 a P < 0.05 versus LDL.
the experimentally measured value of 12% ( 40 ), in line 
with the tendency of atomistic force fi elds to favor helical 
conformations ( 41, 42 ). 
 The equilibrated peptide was then placed in the water 
phase next to the trilayer. Both trilayer compositions were 
considered for this  Unfolded_trilayer simulation. During the 
simulations, the peptide rapidly bound to trilayer surfaces 
of both compositions and began to fold back into a more 
helical structure. At the end of 400 ns simulations, the 
measured average helical contents, shown in supple-
mentary Fig. 3B, were close to 80% with both trilayer com-
positions, suggesting a substantial environment-driven 
conformational change of the peptide. This result suggests 
that the helical conformation of the peptide is the equilib-
rium structure on the trilayer surface. This justifi es the use 
of the extended  Helix_trilayer simulations (in which the he-
lical peptide was observed to bind to the trilayer surface 
without having time to unfold) in studying the long-time 
effects of the peptide on the trilayer surface properties 
(see below). 
 We increased the number of simulations focusing on 
the binding process to increase the statistical signifi cance 
of the fi ndings. However, as the folding of the peptide was 
quite slow on the trilayer surfaces, we considered (instead 
of the unfolded case) the helical structure of the peptide 
as the initial structure that was placed in the vicinity of the 
trilayer (see Materials Methods). Additionally, to increase 
sampling in these  Helix_trilayer simulations, two peptides 
were placed next to the trilayer instead of just one. Out of 
a total of 12 simulated replicas (see Materials and Meth-
ods), the binding of 4F to the trilayer was observed in 
almost all of them regardless of whether the trilayer contained 
ceramide or SM. Additionally, we did not fi nd differences 
in the binding process or fi nal structures between the pep-
tides with different initial orientations or positions. In two 
replicas, one of the peptides diffused through the box 
boundary (allowed by periodic boundary conditions) to 
bind to the other peptide. Due to their amphipathic na-
ture, they formed a stable dimer that resided in the water 
phase for the rest of the simulation. In all other replicas, 
however, the binding of 4F to the trilayer was avid, and the 
two peptides bound either to different monolayers (i.e., 
different sides of the trilayer) or to the same monolayer. 
In the extended simulations (600 ns) considered in some 
of the further analysis, the peptides were attached to sepa-
rate monolayers. 
 To compare the effect of the trilayer composition on 
the binding process more quantitatively, we performed 
umbrella sampling simulations to calculate the free energy 
profi le for the binding process. The free energy profi les, 
shown in  Fig. 5B , display large free energy minima at the 
trilayer surface regardless of the trilayer composition. 
These minima lie at   90 kJ/mol that corresponds to al-
most 40 times the thermal energy at 310 K indicating that 
the association of 4F to the LDL surface is highly irrevers-
ible. The binding to the SM-containing trilayer is slightly 
more favorable than the binding to the ceramide-contain-
ing trilayer, the difference being   7 kJ/mol. The profi les 
also bring out that the partitioning of the peptide to the 
trilayer core is very unfavorable as the free energy grows 
rapidly as the peptide gets closer than 2 nm from the 
trilayer’s center of mass. The location of the free energy 
minimum at 2.5 nm also corresponds to the average peptide-
trilayer distance in the equilibrium simulations, as ex-
pected. This penetration depth can be compared with the 
values obtained by Gorbenko et al. ( 43 ) in their fl uores-
cence resonance energy transfer experiments. They mea-
sured that a tryptophan (Trp) residue of the Ac-18A-NH 2 
peptide, which closely resembles the 4F peptide used in 
this study, lies at   1.5–1.7 nm from the core of a choles-
terol-free phosphatidylcholine (PC) bilayer. We measured 
the distance of the Trp residue of 4F to be 1.3–1.6 nm away 
from the terminal carbon atoms of the POPC and SM/
ceramide tails. This is in good agreement with the experi-
mental value when the much looser packing of our trilayer 
system compared with a PC bilayer is taken into account. 
 As the conformation of the peptide was found to strongly 
depend on the environment (water vs. trilayer surface) 
and was also assumed to affect the free energy profi les, we 
allowed the conformation to relax for 25 ns (175 ns for 
certain windows, see Materials and Methods) prior to data 
collection. The helical content of the peptide in the um-
brella windows, shown with dashed lines in  Fig. 5B , shows 
that the peptide conformation changes quite smoothly 
upon binding to the trilayer. This increase of helical con-
tent close to the trilayer surface suggests that our umbrella 
sampling windows, even with limited sampling time, cap-
ture the binding process properly. 
 The driving force for the strong adsorption of the pep-
tide appears to be of electrostatic origin complemented by 
the hydrophobic effect. The importance of electrostatics is 
highlighted in  Fig. 5C , which shows the electrostatic po-
tential profi le across the lipid trilayer system. One fi nds 
that the electrostatic component of the binding of 4F with 
the lipid trilayer is the strongest in the unmodifi ed system 
(with SM) with a dilute 4F concentration, in agreement 
with the free energy calculations. The binding strength in 
terms of electrostatics becomes weaker if SM is replaced 
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with ceramide, modeling the effect of SMase, or if the con-
centration of 4F at the membrane surface increases. Yet, in 
all cases, the driving force for binding due to electrostatic 
 Fig.  4. The effect of 4F on SMase-premodifi ed LDL. LDL parti-
cles (1.25 mg/ml) were modifi ed with SMase at pH 7.0 for 15 min 
after which lipolysis was stopped and the premodifi ed LDL parti-
cles (1 mg/ml) were incubated with and without L-4F at 10:1 molar 
ratio of 4F to apoB-100. The aggregation of the LDL particles was 
monitored by turbidity (A) and by SEC (B). The inset in B shows 
quantitative analysis of aggregation based on the SEC data. The 
sizes of the LDL particles were measured using DLS (C) at the in-
dicated time points. The results are representative of two indepen-
dent experiments performed with different LDL preparations. 
interactions is substantial, in agreement with experimen-
tal data. 
 The 4F peptide induces structural changes into the lipid 
trilayer. As shown in  Fig. 5D , the deuterium order param-
eter (  S CD ) characterizing conformational order in the 
hydrocarbon chain region increases when 4F binds to the 
lipid surface. This indicates that 4F makes the membrane 
more compact by decreasing the amount of free volume in 
the lipid phase, thus decreasing the average area per lipid, 
and this takes place in both unmodifi ed (with SM) and 
modifi ed (with ceramide) lipid systems. We further stud-
ied the ordering effect of the peptide by calculating the 
  S CD of the palmitate chain of POPC on a two-dimensional 
grid. These spatially resolved order parameters are shown 
in  Fig. 5E for one monolayer in the system containing ce-
ramide, yet the conclusions are also valid for the SM sys-
tem. The results highlight that upon binding to the lipid 
layer, 4F increases conformational disorder in lipids that 
are right under it, but it increases order in lipids outside 
the binding region, and overall the total conformational 
order is promoted due to enhanced packing. We conclude 
that whereas the peptide locally perturbs and disorders 
the membrane, this causes the lipid packing to increase in 
regions not covered by the peptide, and these uncovered 
regions might play a role in LDL aggregation. 
 The specifi city of 4F binding to the lipids was evaluated, 
yet no tendency for any lipid type was observed even during 
the extended  Helix_trilayer simulations (data not shown). 
This may result from the miscibility of the monolayer com-
ponents; as there are no domains present within the surface 
layer, the peptide always interacts with many types of lipids 
upon binding. The strong electrostatic and hydrophobic 
interactions as well as the hydrogen bonds formed with the 
monolayer lipids (data not shown) cause the peptide to 
bury into the head group region and therefore prevent the 
peptide from exchanging its close neighbors even in the 
probed timescales of hundreds of nanoseconds. 
 The stability of the peptide structure on the trilayer sur-
face was evaluated in the  Annealing simulations. In these 
simulations, the peptides remained bound to the trilayer, 
and their structures remained quite stable. The time evo-
lution of the distance between the trilayer and the peptide 
and the peptide root mean squared deviation is shown in 
supplementary Fig. 3C, D. 
 The 4F peptide stabilizes apoB-100 conformation 
by binding and perturbing LDL lipids 
 We further examined the interactions of L-4F with na-
tive LDL particles using SEC. Incubation of native LDL 
particles with 4F at 10:1 molar ratio of 4F to apoB-100 or 
below did not show apparent changes in the SEC profi les 
of LDL ( Fig. 6A ).  DLS analysis also revealed that no 
change in particles size was observed when LDL particles 
were incubated with L-4F at molar ratio of 20:1 or below 
( Fig. 6B ). However, at 40:1 molar ratio of 4F to apoB-100, 
signifi cant increase in LDL particle size and remarkable 
changes in SEC profi les were observed. No signal at 280 nm 
wavelength was detected when the same concentration of 
peptide alone was applied to the column, excluding the 
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 Fig.  5. Atomistic simulations showing that 4F alters the properties of the surface monolayer in protein-free LDL. A: Side view of the initial 
structure of one replica of the  Helix_trilayer simulations with ceramide. Two 4F peptides are positioned in the water phase in the beginning 
of the simulation. Cholesteryl oleate is shown in yellow, POPC in brown, cholesterol in orange, and ceramide in gray. Water is shown in 
blue, and the peptides are depicted with standard atom coloring (carbon, cyan; oxygen, red; hydrogen, white; and nitrogen, blue). B: The 
free energy profi les for the 4F peptide binding to the two trilayer surfaces. Black curves stand for the system with SM (prior to SMase treat-
ment), while red ones show data for the system with ceramide (after SMase treatment). The shaded area shows the statistical error esti-
mated with the bootstrapping analysis. The dashed lines show the average helical contents of the peptide in the umbrella windows. C: The 
electrostatic potential profi le across the lipid trilayer system. Red and black curves show data for trilayers containing ceramide and SM, 
respectively. Dashed lines show results without the bound peptides (one in each leafl et), while solid lines stand for systems with the peptide. 
D: Simulation data for the deuterium order parameter   S CD , characterizing conformational order in the hydrocarbon chain region. Re-
sults are given for the saturated palmitate chains of POPC with the carbon numbering starting from the carbonyl carbon. Coloring as in C. 
E: The   S CD order parameter values of the palmitate chain of POPC given on a two-dimensional grid. Here, the location of the peptide was 
kept constant during the analysis to see the local effects induced by 4F binding. Each column represents data averaged in one grid point. 
The 14 spheres in each column represent the average position of the representative carbon (2nd to 15th carbon in a saturated palmitate 
chain of POPC), whereas their color represents the   S CD value. The lattice structure shown for lipid positions is due to the lipid order 
depicted here on a grid and is thus due to visualization only. In practice, the simulated surface monolayers are always in a fl uid phase . 
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preincubated in buffer alone and directly diluted without dialysis for 
CD measurement. The results are representative of three indepen-
dent experiments performed with different LDL preparations. 
 Fig.  6. The effect of 4F on LDL structure. LDL particles (1 mg/ml) 
were incubated with and without L-4F at the indicated molar ra-
tios of 4F:apoB-100 at pH 7.0 for 30 min. The structure of LDL 
was analyzed by SEC (A), and the sizes of the LDL particles were 
measured using DLS (B). LDL (2 mg/ml) was preincubated with 
and without L-4F at molar ratio of 4F:apoB-100 (10:1), followed 
by extensive dialysis. The control and 4F-pretreated LDL were di-
luted to (50 µg/ml) for far UV-CD measurement (C). The inset in 
C shows the spectrum difference between 4F-pretreated LDL 
and LDL: [  ] 4F-pretreated LDL   [  ] LDL. The green curve 
indicates the CD signal of the same L-4F concentration that was 
 
possibility that peak II contains peptide oligomers (sup-
plementary Fig. 4A). Cholesterol determination showed 
that both peaks contained cholesterol-derived LDL, indi-
cating that 4F can destabilize LDL particles at high con-
centrations (supplementary Fig. 4B). 
 To further obtain an insight into the mechanism by 
which 4F blocks LDL aggregation, we studied the effect of 
4F on the secondary structure of apoB-100, which has pre-
viously been shown to be critical for SMase-induced LDL 
aggregation ( 26 ). We chose the condition at which 4F did 
not affect LDL particle size but did exhibit its protective 
action against SMase-induced LDL aggregation. To ex-
clude the contribution of CD of L-4F per se, LDL particles 
were fi rst pretreated with L-4F at 10:1 molar ratio of 4F to 
apoB-100 for 30 min, followed by extensive dialysis to re-
move unbound L-4F. Compared with control LDL parti-
cles ( Fig. 6C ), the spectra of 4F-pretreated LDL have 
similar shape but show a signifi cant increase in CD intensity, 
indicating that 4F enhanced the   -helix content of apoB-100 
( Fig. 6C ). The difference spectrum (inset) showed a posi-
tive band at 195 nm and two negative bands at 208 nm and 
222 nm, which are characteristics of the   -helix. 
 Furthermore, intrinsic Trp fl uorescence of 4F-pre-
treated LDL showed a signifi cant increase in fl uores-
cence emission, which probably refl ected changes in the 
Trp microenvironment upon interaction with 4F (supple-
mentary Fig. 5). When the same L-4F concentration was 
preincubated in buffer alone and directly diluted, even 
without dialysis, to measure CD and intrinsic Trp fl uores-
cence, no signals were detected ( Fig. 6C ; supplementary 
Fig. 5). Collectively, our data indicated that interaction of 
4F with LDL particles led to conformational change in 
apoB-100. 
 We further investigated whether 4F-induced changes 
in LDL structure would affect the ability of LDL to bind 
to LDL receptor of human skin fi broblast. We found that 
at molar ratio of L-4F to apoB-100 below 20:1, 4F-1,1’-
dioctadecyl- 3,3,3’,3’-tetramethyl-indocarbocyanine per-
chlorate (DiI)-labeled LDL complex displayed LDL recep-
tor binding similar to control DiI-LDL. However, at a 
higher concentration of 4F (e.g., 40:1 molar ratio of 4F to 
apoB-100), 4F-DiI-LDL complex signifi cantly exhibited 
lower binding to LDL receptor (supplementary Fig. 6). 
 The 4F peptide prevents SMase-induced conformational 
changes of apoB-100 
 Next, the 4F-pretreated LDL and control LDL were 
subjected to treatment with bcSMase. SMase treatment 
induced signifi cant conformational changes in apoB-100 
as indicated by the decrease in the   -helix content and 
changes in spectral shape as a function of incubation 
time with SMase ( Fig. 7 ), corroborating our previous 
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 The 4F peptide decreases the binding of SMase-treated 
LDL to human aortic proteoglycans 
 Because SMase-modifi ed lipoprotein particles bind to 
human aortic proteoglycans more strongly than native 
LDL ( 4 ), the effects of 4F on the ability of LDL to bind to 
human aortic proteoglycans were determined. Consistent 
with our previous study ( 4 ), treatment of LDL with bcS-
Mase strongly enhanced the binding of the LDL particles 
to human aortic proteoglycans ( Fig. 8 ).  Interestingly, pre-
treatment of LDL with 4F signifi cantly decreased binding 
of SMase-treated LDL to the proteoglycans. 
fi nding ( 26 ).  Importantly, pretreatment of LDL particles 
with L-4F fully inhibited SMase-induced conformational 
changes of apoB-100 at 15 min, and the inhibition was 
gradually diminished after extended incubation times 
( Fig. 7 ). Although SMase modifi cation was primarily re-
sponsible for conformational changes in apoB-100, we 
could not completely exclude the possibility that the 
light-scattering effect of nonuniform particles could con-
tribute to the CD spectral changes of SMase-treated LDL 
during extended prolongation (over 1 h) when LDL par-
ticle size was gradually increased. 
 Fig.  7.  The 4F peptide prevents SMase-induced 
conformational changes of apoB-100. LDL particles 
(2 mg/ml) were incubated with and without L-4F at 
10:1 molar ratios of 4F to apoB-100 at pH 7.0 for 
30 min, followed by extensive dialysis. Control and 
4F-pretreated LDL (1 mg/ml) were modifi ed with bc-
SMase at pH 7.0 for 15, 30, or 60 min. The samples 
were diluted to (50 µg/ml) for far UV-CD measure-
ment. The results are representative of two indepen-
dent experiments performed with different LDL 
preparations. 
 Fig.  8.  The 4F peptide decreases the binding of 
SMase-modifi ed LDL to human aortic proteoglycan. 
Control and 4F-pretreated LDL particles (1 mg/ml) 
with molar ratio of L-4F to apoB-100 ranging from 
2.5:1 to 20:1 were modifi ed with bcSMase at pH 7.0 
for 15 min and aliquots were added to microtiter 
wells precoated with human aortic proteoglycans. 
The amounts of proteoglycan-bound LDL were deter-
mined by measuring the amounts of cholesterol in 
the wells. The results represent means ± SD from trip-
licate wells and are representative of two indepen-
dent experiments performed with different LDL 
preparations. 
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 Fig.  9. LDLs isolated from L-4F-treated mice are resistant to 
SMase-induced aggregation. LDL particles (0.15 mg/ml) from the 
control or L-4F-treated group were incubated with bcSMase at pH 
7.0, and the sizes of the LDL particles were determined by DLS. 
The results represent average sizes of four different LDL prepara-
tions isolated from the control or L-4F-treated group. 
proteoglycans. Given the pathological relevance of reten-
tion of modifi ed LDL in atherosclerosis ( 2 ), our work re-
veals a novel antiatherogenic functional property of 4F. 
The data indicate that upon interaction with LDL parti-
cles, 4F stabilizes LDL structure and confers LDL particles 
with the ability to resist SMase-induced LDL aggregation. 
 The SMase-induced changes in the lipid monolayer of 
LDL particles lead to remarkable changes in the secondary 
structure of apoB-100 with a dramatic decrease in its 
  -helix content (i.e., structural changes pivotal for LDL 
aggregation) ( 26 ). This earlier fi nding prompted us to de-
fi ne the effects of 4F on the structure of LDL particles. We 
found that following interactions with 4F, the   -helix con-
tent and Trp fl uorescence of apoB-100 in LDL particles 
was slightly enhanced, indicating the local conformational 
changes in LDL structure. As a result, 4F enhanced the 
resistance of LDL particles to SMase-induced alteration of 
apoB-100 conformation. These structural changes of 
apoB-100 could largely result from the ability of the am-
phipathic peptides to strongly bind to and/or sequester 
lipids on the surface of LDL particles ( 17, 20 ), thus per-
turbing lipid distribution in LDL surfaces that consequently 
modulate apoB-100 conformation. Using lipid trilayers to 
mimic the protein-free LDL, our atomistic simulation data 
clearly indicated that 4F bound and inserted into LDL lip-
ids and subsequently induced changes in lipid organiza-
tion in the system. A deep free energy minimum is located 
at the trilayer surface in the case of both unmodifi ed and 
SMase-treated LDL, and the adsorption of 4F to the mem-
brane surface has a strong contribution due to electrostat-
ics, presumably complemented by the hydrophobic effect. 
The electrostatic binding is the strongest prior to SMase 
treatment but remains strong also after the treatment. The 
binding of 4F to the lipids at the LDL surface reduces the 
conformational order of the lipids that are in the vicinity 
of 4F, but the peptide increases the lipids’ order outside 
the 4F binding region, thereby rendering the membrane 
more compressed overall. 
 The perturbation of lipids in LDL particles upon inter-
actions with 4F has been supported by our experimental 
data showing that LDL particles are less susceptible to 
SMase, an enzyme known to be sensitive to lipid pertur-
bation ( 44 ). Thus, the conformational shift of apoB-100 
following 4F interaction is consistent with the results of 
previous studies revealing conformational fl exibility of 
apoB-100 ( 45 ) and also agrees well with the evidence dem-
onstrating lipid-dependent structural changes in specifi c 
domains of apoB-100 ( 46 ). Additionally, although to a 
much smaller degree, we could not rule out the possibility 
that the local structural changes in apoB-100 structure 
might also be related to an ability of 4F to bind directly to 
domains of apoB-100 exposed on the LDL surface. Simi-
larly, 17  -estradiol has been shown to affect conforma-
tional properties of apoB-100 by binding to its specifi c 
domain, thereby stabilizing LDL particles and also pre-
venting LDL aggregation in the presence of electronega-
tive LDL ( 47, 48 ). 
 Interestingly, high concentrations of 4F caused dramatic 
changes in LDL particles, resulting in partial destabilization 
 LDLs isolated from 4F-treated mice are resistant 
to SMase-induced aggregation 
 To further study the potential physiological relevance 
of the observed results in vitro, we intravenously injected 
L-4F (100 µg/mice, the dose corresponding to 20:1 mo-
lar ratio of 4F to apoB-100) into LDLR   /   ApoB 100/100 
mice fed with a high-fat, Western-type diet. When LDL 
isolated from L-4F-treated mice was ex vivo modifi ed with 
SMase, we found that treatment of mice with 4F con-
ferred LDL with ability to resist to SMase-induced aggre-
gation ( Fig. 9 ).  
 DISCUSSION 
 In the present study, we have demonstrated that the 
apoA-I mimetic peptide 4F blocks SMase-induced LDL ag-
gregation and so prevents the SMase-induced increased 
binding of the modifi ed LDL particles to human aortic 
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possibly by local steric hindrance and/or via long-range 
effects on lipid perturbation as evidenced by enzyme kinetics 
and simulation data. The exact nature of the interaction 
between 4F and LDL particles and the molecular charac-
teristics of the interactive domains of apoB-100 remain to 
be defi ned in future studies. Finally, it is important to note 
that in previous studies ( 21, 22 ), amphipathic   -helix-
containing proteins were either present during initial 
perturbation or present in partially aggregated LDL con-
taining both nonaggregated and aggregated LDL parti-
cles; thus, their protective action could also have depended 
on their capacity to affect structural features of LDL 
particles. 
 With respect to molecular mechanisms of action of 4F, 
initial studies ( 14, 55 ) suggested that the biological effects 
of 4F involve remodeling of HDL particles in the plasma 
compartment. However, recent studies ( 56, 57 ) have indi-
cated that the antiatherogenic properties of 4F are largely 
due to its ability to modulate the level of oxidized phos-
pholipids in the intestine. Because the mechanisms by 
which 4F exerts antiatherogenic properties is extremely 
complex ( 57, 58 ), it is likely that 4F may function through 
multiple mechanisms and that combination of these prop-
erties may be responsible for the net in vivo atheroprotec-
tion. In the present study, we have demonstrated that 4F 
suppresses the binding of SMase-modifi ed LDL to proteo-
glycans, thereby providing a novel mechanism for antiath-
erogenic properties of 4F. The physiological relevance of 
the present study has been supported by our ex vivo data 
demonstrating that LDL isolated from L-4F-treated mice 
was less susceptible to SMase-induced aggregation. SMase 
modifi cation perturbs the well-organized surface structure 
of LDL and generates modifi ed particles with enhanced 
affi nity to proteoglycans ( 59 ). Indeed, SMase has been 
demonstrated to play a critical role in the retention of 
LDL particles and so contribute to the development of 
atherosclerotic lesions ( 3, 7, 8 ). In summary, the data indi-
cate that following interactions with LDL particles, 4F al-
ters lipid organization in LDL particles, which subsequently 
induces a stable conformational shift in apoB-100, thereby 
conferring LDL particles with the ability to resist SMase-
induced LDL aggregation and so block the binding of 
SMase-modifi ed LDLs to proteoglycans.  
 Note added in proof 
 The authors of this manuscript informed the  Journal 
there were errors in their original supplemental data 
fi le that was uploaded, specifi cally in the section titled 
“Relaxation of the LDL trilayers to experimental surface 
pressure prior to peptide insertion” (page 2 of the sup-
plemental data fi le) and the list of references (page 8). 
Following Editors-in-Chief and Associate Editor approval 
of these changes, the supplemental data fi le for this man-
uscript has been replaced online and has therefore 
changed from the supplemental data fi le that was origi-
nally accepted as associated with this manuscript. For full 
details on the changes that have been made to the sup-
plemental data fi le, please contact the corresponding 
author. 
of the particles, in an increase in LDL particle size ( Fig. 
6A, B ), and in a decrease in the binding of LDL to LDL 
receptor (supplementary Fig. 6). Such a destabilizing ef-
fect on LDL could be largely related to membrane-lysing 
activity of amphipathic peptides as a result of its pore for-
mation at high concentrations ( 49, 50 ). As the concentra-
tion of 4F increases, the peptide might undergo a dynamic 
reorientation relative to LDL lipid monolayer, resulting in 
the destruction of LDL lipid packing and, eventually, de-
stabilization of LDL particles. 
 Therefore, we aimed at conditions in which concen-
trations required to protect SMase-induced LDL aggrega-
tion did not induce total changes in structure of LDL (i.e., 
molar ratio of 4F to apoB-100 below 20:1). Of note, 4F at 
concentrations used in the present study has been demon-
strated to exhibit its antiatherosclerotic properties in mice 
( 20, 51 ) and to improve functional properties of HDL 
in human plasma ( 10, 52, 53 ). Relevantly, 4F effectively 
blocked SMase-induced LDL aggregation regardless of 
whether 4F was added to partially aggregated LDL, whether 
4F was present during incubation, or whether unbound 4F 
had been removed before SMase modifi cation of LDL. 
Moreover, 4F blocked SMase-induced LDL aggregation 
both at neutral and acidic pH, suggesting that hydropho-
bic interactions between 4F and LDL particles were also of 
importance ( 54 ). SMase-induced aggregation of LDL has 
been shown to depend on the exposure and subsequent 
mutual interactions of hydrophobic domains of apoB-100 
that are buried in native LDL particles ( 26 ). Thus, we envi-
sion that 4F, when present during treatment of LDL with 
SMase or after it, when aggregation of LDL particles has 
already partially taken place, blocks SMase-induced aggre-
gation by interfering with the interactions between the ex-
posed hydrophobic areas of SMase-modifi ed LDL particles 
that are responsible for their aggregation. In analogy, am-
phipathic   -helix-containing proteins and HDL particles 
have been shown to block LDL aggregation, possibly by 
masking hydrophobic interactions between vortexed or 
PLC-modifi ed LDL particles ( 21, 22 ). Indeed, when added 
to partly aggregated LDL, 4F impeded aggregated LDL 
from further aggregation but, on the other hand, failed 
to disassemble the LDL aggregates. Interestingly, 4F did 
not have any effect on completely aggregated LDL particles, 
consistent with previous fi nding showing that amphipathic 
  -helix-containing apoA-I also failed to revert PLC-
induced LDL aggregation ( 22 ). Thus, an additional im-
portant factor underlying the protection of 4F against 
SMase-induced LDL aggregation can be also related to 
interactions between 4F and nonaggregated LDL parti-
cles. This interaction could stabilize the nonaggregated 
particles, thereby suppressing them from further SMase-
induced modifi cation. Indeed, our results deriving from 
experimental conditions in which unbound 4F was re-
moved before SMase modifi cation ( Figs. 3, 6C, and 7 ) in-
dicate the importance of stable conformational shift of 
apoB-100 upon interactions with 4F in determining the 
peptide’s ability to suppress SMase-induced LDL aggrega-
tion. In addition, the binding of 4F to LDL particles also 
prevents SMase from hydrolyzing the SM in LDL particles 
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